The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.
James E. Signorovitch
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Eric Qiong Wu
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Keith A. Betts
Consultant or Advisory Role - Novartis
Research Funding - Novartis
William M. Reichmann
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Darren Thomason
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Philip J Galebach
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Lei Chen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis